Goodwin: ARTBIO Collaborates With AlphaGen Therapeutics, and Enters Into 3 Strategic Agreements to Produce Its Lead Asset AB001
February 28, 2024
February 28, 2024
BOSTON, Massachusetts, Feb. 28 -- Goodwin, a law firm, issued the following news release:
The Life Sciences team advised ARTBIO in its exclusive strategic collaboration agreement with AlphaGen Therapeutics. Under the terms of the exclusive agreement, AlphaGen will use ARTBIO's AlphaDirect isotope isolation technology to generate 212Pb, a unique isotope without a global supply. AlphaGen will also receive rights to develop and commercialize AB001, a clinical-stage alpha radioliga . . .
The Life Sciences team advised ARTBIO in its exclusive strategic collaboration agreement with AlphaGen Therapeutics. Under the terms of the exclusive agreement, AlphaGen will use ARTBIO's AlphaDirect isotope isolation technology to generate 212Pb, a unique isotope without a global supply. AlphaGen will also receive rights to develop and commercialize AB001, a clinical-stage alpha radioliga . . .